Interestingly, several immune checkpoint inhibitors such as anti-CTLA-4 mAb ipilumumab, anti-PD-1 mAbs pembrolizumab and nivolumab, and anti-PD-L1 mAbs avelumab and durvalumab have been approved for a wide range of cancer types. This evidence concerns the gene PDCD1 and cancer.